Evoke Pharma Inc. (EVOK)

3.05
0.00 (0.00)
NASDAQ : Health Technology
Prev Close 3.05
Open 3.10
Day Low/High 2.97 / 3.10
52 Wk Low/High 1.85 / 4.09
Volume 139.54K
Avg Volume 97.10K
Exchange NASDAQ
Shares Outstanding 16.77M
Market Cap 51.16M
EPS -0.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

FDA Approves PDUFA Fee Waiver For Gimoti™ New Drug Application

FDA Approves PDUFA Fee Waiver For Gimoti™ New Drug Application

Cash runway updated into October 2018

Evoke Announces Discovery Of Sex-Based Pharmacokinetic Differences For Gimoti™

Evoke Announces Discovery Of Sex-Based Pharmacokinetic Differences For Gimoti™

Recent Pre-NDA Meeting Provided Guidance on Female Only NDA Filing Strategy and Post-Approval Safety Study

Evoke Pharma Announces Positive Topline Results From Comparative Exposure Pharmacokinetic Study For Gimoti™

Evoke Pharma Announces Positive Topline Results From Comparative Exposure Pharmacokinetic Study For Gimoti™

505(b)(2) NDA on track for FDA submission in Q1 2018

Evoke Pharma Completes Dosing For Gimoti™ Comparative Exposure Pharmacokinetic Study

Evoke Pharma Completes Dosing For Gimoti™ Comparative Exposure Pharmacokinetic Study

Data expected in Q4 2017 followed by a 505(b)(2) NDA submission in late 2017/early 2018

Evoke Pharma Initiates Comparative Exposure Pharmacokinetic Study For Gimoti™

Evoke Pharma Initiates Comparative Exposure Pharmacokinetic Study For Gimoti™

Expected to be final clinical trial prior to 505(b)(2) NDA submission

Evoke Pharma Enters Agreement With Rho To Submit NDA For Gimoti

Company on track for late 2017/early 2018 submission

Evoke Pharma Presents Gimoti Efficacy And Safety Data From Phase 3 Trial As Late Breaker At Digestive Disease Week 2017

Data Demonstrate Gimoti Significantly Improves Symptoms in Women with Moderate to Severe Diabetic Gastroparesis

FDA Exempts Evoke From Requirement For Human Factor Validation Study

Company reaffirms NDA submission by year end 2017